News | March 13, 2021
AstraZeneca Pharma India receives approval for supplying Osimertinib in India
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Combination shows consistent benefit across prespecified post-progression outcomes
The company has received five final approvals
Subscribe To Our Newsletter & Stay Updated
